This company listing is no longer active
Sirona Biochem (SBM) Stock Overview
A cosmetic ingredient and drug discovery company, engages in the development and sale of cosmetic and pharmaceutical active ingredients in Canada and France. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
SBM Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
The Market Is Sleeping on This Parkinson's Biotech - And I Think That's a Mistake
Gain Therapeutics: The Under-the-Radar Biotech With Big Parkinson’s Potential Key Takeaways Gain Therapeutics (GANX) is developing GT-02287 – an oral, first-in-class, potentially disease-modifying treatment for Parkinson’s disease targeting the GCase enzyme pathway. Parkinson’s disease represents a $4 billion U.S. market with zero approved disease-modifying therapies.
Read full narrativeSirona Biochem Corp. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CA$0.06 |
| 52 Week High | CA$0.095 |
| 52 Week Low | CA$0.02 |
| Beta | -0.32 |
| 1 Month Change | 0% |
| 3 Month Change | -7.69% |
| 1 Year Change | 9.09% |
| 3 Year Change | -64.71% |
| 5 Year Change | -77.78% |
| Change since IPO | -45.45% |
Recent News & Updates
Recent updates
Shareholder Returns
| SBM | CA Biotechs | CA Market | |
|---|---|---|---|
| 7D | 0% | 2.3% | 0.2% |
| 1Y | 9.1% | 25.3% | 35.6% |
Return vs Industry: SBM exceeded the Canadian Biotechs industry which returned -3.5% over the past year.
Return vs Market: SBM underperformed the Canadian Market which returned 14.9% over the past year.
Price Volatility
| SBM volatility | |
|---|---|
| SBM Average Weekly Movement | n/a |
| Biotechs Industry Average Movement | 9.8% |
| Market Average Movement | 10.5% |
| 10% most volatile stocks in CA Market | 18.1% |
| 10% least volatile stocks in CA Market | 3.9% |
Stable Share Price: SBM's share price has been volatile over the past 3 months compared to the Canadian market.
Volatility Over Time: Insufficient data to determine SBM's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2006 | n/a | Howard Verrico | www.sironabiochem.com |
Sirona Biochem Corp., a cosmetic ingredient and drug discovery company, develops and sells cosmetic and pharmaceutical active ingredients in Canada and France. Its programs include cosmetic skin lightener and diabetes drug; and other projects comprise the development of an anti-aging/cell protection library, novel anti-wrinkle compound, and anti-viral program. The company was formerly known as High Rider Capital Inc. and changed its name to Sirona Biochem Corp. in May 2009.
Sirona Biochem Corp. Fundamentals Summary
| SBM fundamental statistics | |
|---|---|
| Market cap | CA$15.82m |
| Earnings (TTM) | -CA$2.67m |
| Revenue (TTM) | n/a |
Is SBM overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| SBM income statement (TTM) | |
|---|---|
| Revenue | -CA$16.36k |
| Cost of Revenue | CA$65.13k |
| Gross Profit | -CA$81.49k |
| Other Expenses | CA$2.58m |
| Earnings | -CA$2.67m |
Last Reported Earnings
Jul 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.01 |
| Gross Margin | 498.01% |
| Net Profit Margin | 16,294.87% |
| Debt/Equity Ratio | -95.8% |
How did SBM perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/06/02 01:45 |
| End of Day Share Price | 2025/03/05 00:00 |
| Earnings | 2024/07/31 |
| Annual Earnings | 2023/10/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Sirona Biochem Corp. is covered by 2 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Ellis Acklin | First Berlin Equity Research GmbH |
| Jens Hasselmeier | First Berlin Equity Research GmbH |